Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma-predominant testis cancer

Journal of Clinical Oncology

Volumn 18, Issue 2, 2000, Pages 358-362

  Sweeney, Christopher J ^a   Hermans, Benoit P ^a   Heilman, Douglas K ^a   Foster, Richard S ^a   Donohue, John P ^a   Einhorn, Lawrence H ^a  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; EMBRYONAL CARCINOMA; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TESTIS CARCINOMA;

EID: 0033979224     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.2.358     Document Type: Article

References (19)

1. Einhorn LH: Testicular cancer as a model for a curable neoplasm. Cancer Res 41:3275-3280, 1981
2. Bosl GJ, Motzer RJ: Testicular germ cell cancers. N Engl J Med 337:242-253, 1997
3. Narayan P, Lange PH, Fraley EE: Ejaculation and fertility after extended retroperitoneal lymph node dissection for testicular cancer. J Urol 127:685-688, 1982
4. Freedman LS, Parkinson MC, Jones WG, et al: Histopathology in the prediction of relapse of patients with stage I testicular teratoma by orchiectomy alone. Lancet 2:294-297, 1987
5. Sogani PC, Perrotti M, Herr HW, et al: Clinical stage I testis cancer: Long term outcome of patients on surveillance. J Urol 159: 855-858, 1998
6. Donohue JP, Thornhill JA, Foster RS, et al: Retroperitoneal lymphadenectomy for clinical stage I testis cancer (1965-1989): Modifications of technique and impact on ejaculation. J Urol 149:237-243, 1993
7. Cullen MH, Stenning SP, Parkinson MC, et al: Short course of adjuvant chemotherapy in high risk stage I non-seminomatous germ cell tumors of the testis (NSGCTT): An MRC study report. Proc Am Soc Clin Oncol 14:244, 1995 (abstr)
8. Pont J, Albrecht W, Postner G, et al: Adjuvant chemotherapy for high-risk clinical stage I non-seminomatous testicular germ cell cancer: Long-term results of a prospective trial. J Clin Oncol 14:441-448, 1996
9. Baniel J, Foster RS, Rowland R, et al: Complications of primary retroperitoneal lymph node dissection. J Urol 152:424-427, 1994
10. Donohue JP, Thornhill JA, Foster RS, et al: Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer: Review of the Indiana University experience 1965-1989. Br J Urol 71:326-335, 1993
11. Hao D, Seidel J, Brant R, et al: Compliance of clinical stage I nonseminomatous germ cell tumor patients with surveillance. J Urol 160:768-71, 1998
12. Young BJ, Bultz BD, Russell JA, et al: Compliance with follow-up of patients treated for non-seminomatous testicular cancer. Br J Cancer 64:606-608, 1991
13. Drasga RE, Einhorn LH, Willams SD, et al: Fertility after chemotherapy for testicular cancer. J Clin Oncol 1:179-183, 1983
14. Lange PH, Narayan P, Vogelzang NJ, et al: Return of fertility after treatment for nonseminomatous testicular cancer: Changing concepts. J Urol 129:1131-1135, 1983
15. Petersen PM, Hansen SW, Giwercmann A, et al: Dose dependent impairment of testicular function in patients treated with cisplatinbased chemotherapy for germ cell tumors. Ann Oncol 5:355-358, 1994
16. Nichols CR, Breeden ES, Loehrer PJ, et al: Secondary leukemia associated with a conventional dose of etoposide: Review of serial germ cell tumor protocols. J Natl Cancer Inst 85:36-40, 1993
17. Pedersen-Bjergaard J, Daugaard G, Werner Hansen S, et al: Increased risk of myelodysplasia and leukemia after etoposide, cisplatin and bleomycin for germ cell tumors. Lancet 331:359-363, 1991
18. Read G, Stenning SG, Cullen MH, et al: Medical Research Council Prospective Study of Surveillance for stage I testicular teratoma. J Clin Oncol 10:1762-1768, 1992
19. Dearnaley DP, Fossa SD, Kaye SJ, et al: Adjuvant bleomycin, vincristine and cisplatin for high risk clinical stage I (HRCS1) non-seminomatous germ cell tumors (NSGCT): A Medical Research Council (MRC) Pilot Study. Proc Am Soc Clin Oncol 17:309, 1998 (abstr)